相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines
Carlo Visco et al.
BLOOD CELLS MOLECULES AND DISEASES (2012)
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents
Lorenzo M. Leoni et al.
CLINICAL CANCER RESEARCH (2008)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
K. Sue Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
Alexander Schmittel et al.
LUNG CANCER (2007)
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone -: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC
G von Minckwitz et al.
ANTI-CANCER DRUGS (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential
KU Chow et al.
LEUKEMIA & LYMPHOMA (2003)
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
K Bremer
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia
C Schwänen et al.
LEUKEMIA (2002)
Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies
V Gandhi
SEMINARS IN ONCOLOGY (2002)
分享论文
